Overview

Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX® as part of the Belgium Medical Needs Program.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Criteria
Inclusion Criteria:

- Macular oedema in at least one eye due to branch retinal vein occlusion (BRVO) or
central retinal vein occlusion (CRVO)

- Received at least two OZURDEX® injections in the study eye as part of the Belgium
Medical Needs Program

Exclusion Criteria:

- None